Ru58841 vs Finasteride
Which Is Right for You? Complete Comparison (2026)
Compare topical RU58841 with oral Finasteride for androgenetic alopecia. Understand systemic DHT reduction vs localized receptor blockade and side effect.
Ru58841 vs Finasteride: At a Glance
- ✓Topical non-steroidal androgen receptor antagonist
- ✓Blocks DHT binding at the hair follicle level
- ✓Minimal systemic absorption — avoids sexual side effects
- ✓Never completed clinical trials — abandoned by developer
- ✓Used off-label in hair loss community
- ✓FDA-approved 5-alpha reductase inhibitor (type II)
- ✓Reduces serum DHT by ~70%
- ✓FDA-approved for male pattern hair loss (Propecia) and BPH (Proscar)
- ✓Oral — once daily dosing
- ✓Extensive long-term safety data (25+ years on market)
Detailed Comparison
| Feature | Ru58841 | Finasteride |
|---|---|---|
| Mechanism | Non-steroidal antiandrogen | 5-alpha reductase inhibitorBest |
| Dosing | 25-50 mg in topical solution daily | 1 mg orally daily (hair loss); 5 mg daily (BPH) |
| Administration | Topical | Oral |
| Half-life | Topical — local effect | ~6-8 hours |
| FDA Status | Not FDA-approved — abandoned research compound | FDA-approved (Propecia, Proscar) |
| Key Trial | Battmann T et al. J Steroid Biochem Mol Biol 1994 — characterization | Kaufman KD et al. JAAD 1998 — 5-year efficacy data |
| Side Effects | Scalp irritation; unknown long-term safety (no completed trials) | Sexual dysfunction (1-2%), gynecomastia, depression (rare) |
Which Should You Choose?
RU58841 (non-steroidal antiandrogen) and Finasteride (5-alpha reductase inhibitor) serve different clinical roles despite both being in the Hair loss compound space. RU58841 topical non-steroidal antiandrogen that blocks dht binding to androgen receptors in hair follicles without systemic anti-androgenic effects. Finasteride competitive inhibitor of type ii 5-alpha reductase that reduces dht conversion by ~70%, slowing androgenetic alopecia and shrinking prostate.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Ru58841 and Finasteride
Choosing between Ru58841 and Finasteride depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Ru58841 and Finasteride is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Ru58841 vs Finasteride: Frequently Asked Questions
RU58841 is a non-steroidal antiandrogen while Finasteride is a 5-alpha reductase inhibitor. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
RU58841 works as a non-steroidal antiandrogen (25-50 mg in topical solution daily), while Finasteride is a 5-alpha reductase inhibitor (1 mg orally daily (hair loss); 5 mg daily (BPH)). They have different half-lives (Topical — local effect vs ~6-8 hours), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Ru58841 or Finasteride in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.